SAN DIEGO, May 11, 2017 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market today provided a business update and reported financial results for the first quarter 2017.
“We are extremely pleased with the progress made during the quarter,” said Kim Kamdar, Ph.D., a member of Neothetics’ Operating Committee and Board of Directors. “If approved, LIPO-202 could be the first non-ablative option for submental fat reduction. We remain on track and look forward to reporting top-line results from our Phase 2 proof of concept trial for the reduction of submental fat in late June of this year.”
“We are extremely pleased with the progress made during the quarter,” said Kim Kamdar, Ph.D., a member of Neothetics’ Operating Committee and Board of Directors. “If approved, LIPO-202 could be the first non-ablative option for submental fat reduction. We remain on track and look forward to reporting top-line results from our Phase 2 proof of concept trial for the reduction of submental fat in late June of this year.”
